95 related articles for article (PubMed ID: 21512070)
1. Role of limited whole-body PET/CT in pediatric lymphoma.
Sammer MB; Shulkin BL; Alessio A; Parisi MT
AJR Am J Roentgenol; 2011 May; 196(5):1047-55. PubMed ID: 21512070
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE
Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET and PET/CT in Burkitt's lymphoma.
Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA
Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248
[TBL] [Abstract][Full Text] [Related]
4. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
5. Newly diagnosed lymphoma: initial results with whole-body T1-weighted, STIR, and diffusion-weighted MRI compared with 18F-FDG PET/CT.
van Ufford HM; Kwee TC; Beek FJ; van Leeuwen MS; Takahara T; Fijnheer R; Nievelstein RA; de Klerk JM
AJR Am J Roentgenol; 2011 Mar; 196(3):662-9. PubMed ID: 21343511
[TBL] [Abstract][Full Text] [Related]
6. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
8. In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.
Wild D; Eyrich GK; Ciernik IF; Stoeckli SJ; Schuknecht B; Goerres GW
J Craniomaxillofac Surg; 2006 Jan; 34(1):9-16. PubMed ID: 16343913
[TBL] [Abstract][Full Text] [Related]
9. Is there an added clinical value of "true"whole body(18)F-FDG PET/CT imaging in patients with malignant melanoma?
Tan JC; Chatterton BE
Hell J Nucl Med; 2012; 15(3):202-5. PubMed ID: 23106051
[TBL] [Abstract][Full Text] [Related]
10. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
11. Value of true whole-body FDG-PET/CT scanning protocol in oncology: optimization of its use based on primary diagnosis.
Sebro R; Mari-Aparici C; Hernandez-Pampaloni M
Acta Radiol; 2013 Jun; 54(5):534-9. PubMed ID: 23463863
[TBL] [Abstract][Full Text] [Related]
12. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2001 Mar; 86(3):266-73. PubMed ID: 11255273
[TBL] [Abstract][Full Text] [Related]
13. Pediatric and adolescent lymphoma: comparison of whole-body STIR half-Fourier RARE MR imaging with an enhanced PET/CT reference for initial staging.
Punwani S; Taylor SA; Bainbridge A; Prakash V; Bandula S; De Vita E; Olsen OE; Hain SF; Stevens N; Daw S; Shankar A; Bomanji JB; Humphries PD
Radiology; 2010 Apr; 255(1):182-90. PubMed ID: 20308456
[TBL] [Abstract][Full Text] [Related]
14. Whole-body 18F-FDG PET/CT in the presence of truncation artifacts.
Beyer T; Bockisch A; Kühl H; Martinez MJ
J Nucl Med; 2006 Jan; 47(1):91-9. PubMed ID: 16391192
[TBL] [Abstract][Full Text] [Related]
15. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
16. (18)F-FDG-PET/CT of orofacial tumors, a value of whole-body imaging approach.
Ferda J; Ferdová E; Záhlava J; Walter J; Mukensnabl P; Daum O; Kreuzberg B
Eur J Radiol; 2010 Feb; 73(2):241-8. PubMed ID: 19101104
[TBL] [Abstract][Full Text] [Related]
17. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
[TBL] [Abstract][Full Text] [Related]
18. Role of whole body positron emission tomography/computed tomography scan with 18F-fluorodeoxyglucose in patients with biopsy proven tumor metastases from unknown primary site.
Pelosi E; Pennone M; Deandreis D; Douroukas A; Mancini M; Bisi G
Q J Nucl Med Mol Imaging; 2006 Mar; 50(1):15-22. PubMed ID: 16557200
[TBL] [Abstract][Full Text] [Related]
19. Is True Whole-Body
Cerci JJ; Etchebehere EC; Nadel H; Brink A; Bal CS; Rangarajan V; Pfluger T; Kagna O; Alonso O; Begum FK; Mir KB; Magboo VP; Menezes LJ; Paez D; Pascual TN
J Nucl Med; 2019 Aug; 60(8):1087-1093. PubMed ID: 30683766
[TBL] [Abstract][Full Text] [Related]
20. FDG PET-CT in the management of primary breast lymphoma.
Santra A; Kumar R; Reddy R; Halanaik D; Kumar R; Bal CS; Malhotra A
Clin Nucl Med; 2009 Dec; 34(12):848-53. PubMed ID: 20139815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]